#LifeScienceRevolution: Proximity to Resources with KaloCyte – Part 3 of 4

We’re recording this episode at Maryland Life Sciences’ first annual Bio Innovation Conference, which was held on October 7, 2019. Marty Rosendale, CEO of MTC and host of the Capital M podcast, sits down with conference attendees to discuss access to capital and workforce issues in Maryland and the Mid-Atlantic.
 
In this episode, Marty discusses business in Maryland with Elaine Haynes, President and CEO of KaloCyte, a pre-clinical biotech startup developing a synthetic red blood cell substitute. KaloCyte recently relocated to Baltimore, and Elaine reveals how, for a biotech startup, Maryland has a “set of benefits that you can’t replicate anywhere else in the country.” For her, the biggest benefit has been the proximity to government agencies, which is accelerating her ability to access non-dilutive funding.